TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Problems

A focus on progestogens in hormone replacement therapy

Key Statistics

  • 12–14 days — Minimum sequential progestogen/month
  • 100 mg — Micronised progesterone, daily continuous
  • +8–10/1000 — Excess breast cancers, 5y combined HRT

Don't-miss facts

  1. Uterus present + estrogen = progestogen required. Sequential 12–14 days/month; continuous only if >1 year post- menopause

  2. Micronised progesterone: 200 mg ×12–14 days/month sequential; 100 mg daily continuous. Vaginal dose = oral dose (off- licence)

  3. Only Mirena® 52 mg licensed for endometrial protection (4 years). Jaydess®/Kyleena® need additional progestogen

  4. Persistent unscheduled bleeding >4 months → alter dose/route → USS: biopsy/hysteroscopy if ET ≥4 mm continuous or ≥7 mm sequential

  5. VTE risk factors → transdermal estrogen + oral micronised progesterone or combined patch. Oral HRT ↑VTE 2–4×, worst in year 1

  6. Breast cancer: combined HRT +8 to +10 extra cases/1000 over 5 years (age 50–59) – comparable to obesity (+10) and alcohol (+8 to +11)

  7. Remove the LNG-IUS on diagnosis of breast cancer; personal history of breast cancer usually contraindicates systemic HRT

  8. Debilitating progestogenic mood effects → halve dose or 7–10 days/month (warn ↑hyperplasia risk), or switch to LNG-IUS / patch / vaginal route

Progestogen risk profile at a glance

Lowest VTE/breast risk: micronised progesterone, dydrogesterone Fewest systemic side effects: LNG-IUS, vaginal progesterone

Highest VTE: oral estrogen + MPA (OR 2.10) Not for HRT in UK: norpregnanes, progestogen cream

Abbreviation Key

  • HRT — hormone replacement therapy
  • WHIMS — WHI Memory Study
  • PR — progesterone receptor
  • PEPI — Postmenopausal Estrogen/Progestin Interventions trial
  • MPA — medroxyprogesterone acetate
  • CGHFBC — Collaborative Group on Hormonal Factors in Breast Cancer
  • NET — norethisterone
  • VTE — venous thromboembolism
  • LNG-IUS — levonorgestrel intrauterine system
  • BMS — British Menopause Society
  • CEE — conjugated equine estrogen
  • HR / RR / OR — hazard ratio / relative risk / odds ratio
  • WHI — Women’s Health Initiative

Source: Ghosh S, Imrie R, Goadsby J, Savvas M. A focus on progestogens in hormone replacement therapy. The Obstetrician & Gynaecologist 2023;25:263–271. doi:10.1111/tog.12898

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free